Drugs / 18FET
18FET
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07360548 | Sep 2026 → Sep 2030 expected | functioning pituitary gland adenoma | University Hospital, Lille | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18FET | “The protocol consists of a single arm involving the administration of the radiopharmaceutical 18FET (IASOglio).” NCT07360548 ↗ |
| Known as | [18F]Fluoroethyl-L-tyrosine | “The experimental drug is \[18F\]Fluoroethyl-L-tyrosine, produced in accordance with Good Manufacturing Practices (GMP) guidelines and marketed under the name IASOglio by Curium...” NCT07360548 ↗ |
| Known as | fluoroethyl-L tyrosine (18F) | “Drug: fluoroethyl-L tyrosine (18F)” NCT07360548 ↗ |
| Known as | IASOglio | “The experimental drug is \[18F\]Fluoroethyl-L-tyrosine, produced in accordance with Good Manufacturing Practices (GMP) guidelines and marketed under the name IASOglio by Curium...” NCT07360548 ↗ |